ad01

BZAD01 is a selective NMDA NR1A/2B receptor antagonist.

AD015 is a dual inhibitor of angiotensin-converting enzyme (ACE) and neprilysin (NEP), effectively inhibiting NEP, nACE, and cACE with IC50 values of 0.009, 0.019, and 0.0008 μM, respectively.

AD013 is a dual cACE and NEP inhibitor. AD013 is a C-domain selective ACE inhibitor of lenopril-tryptophan synthesis. AD013 has the potential to provide potent anti-hypertensive and cardioprotective effects.

AD012 is a dual inhibitor of cACE NEP that utilizes the previously reported C-domain selective ACE inhibitor lenopril-tryptophan synthesis, potentially offering potent anti-hypertensive and cardioprotective effects.

AD011 is a dual cACE NEP inhibitor. AD011 was synthesized via the previously reported C-domain selective ACE inhibitor lenopril-tryptophan. AD011 shows potential to provide potent anti-hypertensive and cardioprotective effects.

FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration a